Kymab's $40m financing is 'strong scientific endorsement'
This article was originally published in Scrip
Executive Summary
Cambridge, UK-based biopharmaceutical firm Kymab has received $40m in funding from the Bill and Melinda Gates Foundation and the Wellcome Trust in order to advance its portfolio of monoclonal antibodies.